<?xml version='1.0' encoding='utf-8'?>
<document id="27278712"><sentence text="Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects."><entity charOffset="84-97" id="DDI-PubMed.27278712.s1.e0" text="Isavuconazole" /><entity charOffset="102-110" id="DDI-PubMed.27278712.s1.e1" text="Warfarin" /><pair ddi="false" e1="DDI-PubMed.27278712.s1.e0" e2="DDI-PubMed.27278712.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27278712.s1.e0" e2="DDI-PubMed.27278712.s1.e1" /></sentence><sentence text="This phase 1 trial evaluated pharmacokinetic and pharmacodynamic interactions between the novel triazole antifungal agent isavuconazole and warfarin in healthy adults"><entity charOffset="96-104" id="DDI-PubMed.27278712.s2.e0" text="triazole" /><entity charOffset="122-135" id="DDI-PubMed.27278712.s2.e1" text="isavuconazole" /><entity charOffset="140-148" id="DDI-PubMed.27278712.s2.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.27278712.s2.e0" e2="DDI-PubMed.27278712.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27278712.s2.e0" e2="DDI-PubMed.27278712.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27278712.s2.e0" e2="DDI-PubMed.27278712.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s2.e1" e2="DDI-PubMed.27278712.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27278712.s2.e1" e2="DDI-PubMed.27278712.s2.e2" /></sentence><sentence text=" Multiple doses of isavuconazole were administered as the oral prodrug, isavuconazonium sulfate (372 mg 3 times a day for 2 days loading dose, then 372 mg once daily thereafter; equivalent to isavuconazole 200 mg), in the presence and absence of single doses of oral warfarin sodium 20 mg"><entity charOffset="19-32" id="DDI-PubMed.27278712.s3.e0" text="isavuconazole" /><entity charOffset="72-95" id="DDI-PubMed.27278712.s3.e1" text="isavuconazonium sulfate" /><entity charOffset="192-205" id="DDI-PubMed.27278712.s3.e2" text="isavuconazole" /><entity charOffset="267-282" id="DDI-PubMed.27278712.s3.e3" text="warfarin sodium" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e0" e2="DDI-PubMed.27278712.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e0" e2="DDI-PubMed.27278712.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e0" e2="DDI-PubMed.27278712.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e0" e2="DDI-PubMed.27278712.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e1" e2="DDI-PubMed.27278712.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e1" e2="DDI-PubMed.27278712.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e1" e2="DDI-PubMed.27278712.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e2" e2="DDI-PubMed.27278712.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s3.e2" e2="DDI-PubMed.27278712.s3.e3" /></sentence><sentence text=" Coadministration with isavuconazole increased the mean area under the plasma concentration-time curves from time 0 to infinity of S- and R-warfarin by 11% and 20%, respectively, but decreased the mean maximum plasma concentrations of S- and R-warfarin by 12% and 7%, respectively, relative to warfarin alone"><entity charOffset="23-36" id="DDI-PubMed.27278712.s4.e0" text="isavuconazole" /><entity charOffset="138-148" id="DDI-PubMed.27278712.s4.e1" text="R-warfarin" /><entity charOffset="235-237" id="DDI-PubMed.27278712.s4.e2" text="S-" /><entity charOffset="242-252" id="DDI-PubMed.27278712.s4.e3" text="R-warfarin" /><entity charOffset="131-140" id="DDI-PubMed.27278712.s4.e4" text="S-" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e0" e2="DDI-PubMed.27278712.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e0" e2="DDI-PubMed.27278712.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e0" e2="DDI-PubMed.27278712.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e0" e2="DDI-PubMed.27278712.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e0" e2="DDI-PubMed.27278712.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e4" e2="DDI-PubMed.27278712.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e4" e2="DDI-PubMed.27278712.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e4" e2="DDI-PubMed.27278712.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e4" e2="DDI-PubMed.27278712.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e1" e2="DDI-PubMed.27278712.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e1" e2="DDI-PubMed.27278712.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e1" e2="DDI-PubMed.27278712.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e2" e2="DDI-PubMed.27278712.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27278712.s4.e2" e2="DDI-PubMed.27278712.s4.e3" /></sentence><sentence text=" Mean area under the international normalized ratio curve and maximum international normalized ratio were 4% lower in the presence vs absence of isavuconazole"><entity charOffset="145-158" id="DDI-PubMed.27278712.s5.e0" text="isavuconazole" /></sentence><sentence text=" Mean warfarin area under the prothrombin time curve and maximum prothrombin time were 3% lower in the presence vs absence of isavuconazole"><entity charOffset="126-139" id="DDI-PubMed.27278712.s6.e0" text="isavuconazole" /></sentence><sentence text=" There were no serious treatment-emergent adverse events (TEAEs), and no subjects discontinued the study due to TEAEs" /><sentence text=" All TEAEs were mild in intensity" /><sentence text=" These findings indicate that coadministration with isavuconazole has no clinically relevant effects on warfarin pharmacokinetics or pharmacodynamics"><entity charOffset="52-65" id="DDI-PubMed.27278712.s9.e0" text="isavuconazole" /></sentence><sentence text="" /></document>